Memantine

Drugs and Aging

Volumn 20, Issue 6, 2003, Pages 465-476

  Jarvis, Blair ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FALLING; HALLUCINATION; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE; VERTIGO;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS; DEMENTIA; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0037565267     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320060-00005     Document Type: Review

References (56)

1. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999 Nov 25; 341: 1670-9
2. Amar K, Wilcock G. Vascular dementia. Br Med J 1996 Jan 27; 312: 227-31
3. Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs 1999 Jul; 12: 35-48
4. Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 1999; 14 (1): 3-47
5. Fischer P-A, Jacobi P, Schneider E, et al. Effects of intravenous administration of memantine in Parkinsonian patients (in German]. Arzneimittelforschung 1977; 27 (II) (7): 1487-9
6. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome: a double-blind, placebo controlled trial. Arzneimittelforschung 1991 Aug; 41 (8): 773-80
7. Görtelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebo-controlled study. Arzneimittelforschung 1992 Jul; 42 (7): 904-13
8. Pantev M, Ritter R, Görtelmeyer R. Clinical and behavioural evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Zeitschrift Fur Gerontopsychologie Und -Psychiatrie 1993; 6: 103-17
9. Grossmann W, Schütz W. Memantine and neurogenic bladder dysfunction in spastic conditions (in German). Arzneimittelforschung 1982; 32 (II) (10): 1273-6
10. Miltner FO. Use of symptomatic therapy with memantine in cerebral coma. I. Correlation of coma stages and EEG spectral patterns (in German). Arzneimittelforschung 1982; 32 (10): 1268-70
11. Winblad B, Möbius HJ, Stöffler A. Glutamate receptors as a target for Alzheimer's disease - are clinical results supporting the hope? J Neural Transm 2002; 62 Suppl.: 217-25
12. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs 2002; 16 (12): 811-24
13. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry 1988 May; 21 (3): 144-6
14. Chen H-S, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992 Nov; 12 (11): 4427-36
15. Chen H-S, Lipton SA. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol 1997 Feb 15; 499 (Pt 1): 27-46
16. Rohrbacher J, Bijak M, Misgeld U. Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices. Neurosci Lett 1994 Nov 21; 182 (1): 95-8
17. Parsons CG, Panchenko VA, Pinchenko VO, et al. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996 Mar; 8 (3): 446-54
18. Frankiewicz T, Potier B, Bashir ZI, et al. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 1996 Feb; 117 (4): 689-97
19. Sobolevsky AI, Koshelev SG, Khodorov BI. Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J Physiol 1998 Oct 1; 512 (Pt 1): 47-60
20. Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 1999 Sep; 38 (9): 1253-9
21. Blanpied TA, Boeckman FA, Aizenman E, et al. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997 Jan; 77 (1): 309-23
22. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989 Aug 3; 166 (3): 591-2
23. Parsons CG, Gruner R, Rozental J, et al. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5- dimethyladamantan). Neuropharmacology 1993 Dec; 32 (12): 1337-50
24. Krieglstein J, Lippert K, Pöch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology 1996; 35 (No. 12): 1737-42
25. Erdö SL, Schafer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur J Pharmacol 1991 Jun 6; 198 (2-3): 215-7
26. Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993; 613: 143-8
27. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993 Apr; 33 (4): 403-7
28. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001 Jun 22; 306 (1-2): 81-4
29. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997 Feb; 83 (1-2): 129-33
30. Rao VLR, Dogan A, Todd KG, et al. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 2001 Aug 17; 911 (1): 96-100
31. Görgülü A, Kins T, Çobanoglu S, et al. Reduction of edema and infarction by memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir (Wien) 2000; 142 (11): 1287-92
32. Dogan A, Eras MA, Rao VLR, et al. Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir (Wien) 1999; 141 (10): 1107-13
33. Seif el Nasr M, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990 Aug 21; 185 (1): 19-24
34. Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm 1995; 46 Suppl.: 117-30
35. Stieg PE, Sathi S, Warach S, et al. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 1999 Jun 30; 375 (1-3): 115-20
36. Keilhoff G, Wolf G. Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol 1992 Sep 4; 219 (3): 451-4
37. Marvanová M, Lakso M, Pirhonen J, et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001 Sep; 18 (3): 247-58
38. Schwenkreis P, Witscher K, Janssen F, et al. Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 1999 Aug 6; 270 (3): 137-40
39. Schugens MM, Egerter R, Daum I, et al. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett 1997 Mar 7; 224 (1): 57-60
40. Schulz H, Jobert M, Coppola R, et al. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology 1996; 33 (1): 32-40
41. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem 2001; 8 (1): 20-5
42. H. Lundbeck A/S. Summary of product characteristics. Ebixa (memantine hydrochloride). H. Lundbeck A/S, Valby, Denmark. 2002, 1-13
43. Wenk GL, Quack G, Moebius HJ, et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000 Feb 11; 66 (12): 1079-83
44. Periclou A, Ventura D, Sherman T, et al. Pharmacokinetic study of memantine and donepezil in healthy young subjects [poster no. 32]. 26th Annual Meeting of the American Medical Directors Association; 2003 Mar 6-9; Orlando
45. Reisberg B, Doody R, Stöffler A, et al. A randomized, placebo-controlled study of memantine, an uncompetitive NMDA antagonist, in patients with moderate to severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
46. Reisberg B, Möbius HJ, Stöffler A, et al. Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderately severe to severe Alzheimer's disease [abstract]. 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm July 20-25 2000
47. Ferris SH, Schmidt F, Doody R, et al. Long-term treatment with the NMDA antagonist, memantine: results of a 24-week, open-label extension study in advanced Alzheimer's Disease [poster]. Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa Village, Hawaii Dec 9-13 2001
48. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14 (2): 135-46
49. Orgogozo J-M, Rigaud A-S, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002 Jul; 33 (7): 1834-9
50. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002 Nov; 17 (6): 297-305
51. Farlow MR, Tariot PN, Grossberg GT, et al. Memantine/ donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease [abstract no. 1035]. Neurology 2003; 60 Suppl. 1: A412
52. Wimo A, Winblad B, Stöffler A, et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21 (5): 327-40
53. Wilcock G, Stoeffler A, Sahin K, et al. Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment: a subgroup analysis of two placebo-controlled clinical trials in vascular dementia [abstract]. Ear Neuropsychopharmacol 2000 Sep; 10 Suppl. 3: S360
54. Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003 Mar; 18 (2): 81-5
55. Forest Laboratories. New study shows improved cognition relative to baseline for Alzheimer's patients treated with investigational memantine and donepezil (Accessed 17 Dec 2002) [media release]. 2002
56. Forest Laboratories. Forest Laboratories submits New Drug Application for investigational Alzheimer's treatment memantine (Accessed 16 Apr 2002) [media release]. 2002